Equities

Lifecore Biomedical Inc

Lifecore Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.74
  • Today's Change0.540 / 10.38%
  • Shares traded93.11k
  • 1 Year change-30.34%
  • Beta0.9322
Data delayed at least 15 minutes, as of Sep 19 2024 16:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

  • Revenue in USD (TTM)128.26m
  • Net income in USD9.33m
  • Incorporated2007
  • Employees524.00
  • Location
    Lifecore Biomedical Inc3515 Lyman BoulevardCHASKA 55318United StatesUSA
  • Phone+1 (952) 368-4300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lifecore.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LifeVantage Corp200.16m2.94m126.54m217.0045.114.8819.410.63220.22480.224815.512.083.172.6687.77922,414.804.659.956.9515.5579.3081.451.473.081.01--0.0026.95-6.20-2.4015.63-16.94-2.18--
OptiNose Inc75.06m-40.91m128.16m132.00------1.71-0.3479-0.34790.6195-0.28630.63090.79093.50568,621.20-34.39-48.25-199.84-98.9589.9286.96-54.50-131.663.59-0.85371.52---6.9358.6452.58---27.96--
Elutia Inc24.99m-70.10m131.47m54.00------5.26-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Eton Pharmaceuticals Inc31.38m-6.69m152.69m30.00--11.30--4.87-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Biostem Technologies Inc131.44m7.87m158.96m67.0029.178.7819.661.210.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Lifecore Biomedical Inc128.26m9.33m160.67m524.0035.0914.058.831.250.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
ASP Isotopes Inc2.30m-27.05m177.39m76.00--12.59--77.27-0.628-0.6280.05490.21120.068----30,206.32-71.81---89.44--36.54---1,055.85-----8.110.6748-------229.34------
Telomir Pharmaceuticals Inc0.00-18.74m177.66m1.00--113.33-----0.6855-0.68550.000.05290.00----0.00-467.16---686.91-------------0.92990.00-------1,430.39------
Greenwich Lifesciences Inc0.00-10.22m186.26m3.00--31.52-----0.7942-0.79420.000.44960.00----0.00-112.41-36.43-123.67-38.31------------0.00-------13.63------
Mediwound Ltd20.14m-19.97m189.52m100.00--9.13--9.41-2.16-2.162.181.920.33115.536.55201,410.00-32.83-24.48-49.28-32.9213.2543.27-99.17-38.431.51-3.260.2623---29.4840.6065.73--64.66--
Scilex Holding Co50.83m-171.53m193.71m113.00------3.81-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Amylyx Pharmaceuticals Inc298.76m-165.87m196.08m384.00--0.7503--0.6563-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Data as of Sep 19 2024. Currency figures normalised to Lifecore Biomedical Inc's reporting currency: US Dollar USD

Institutional shareholders

54.76%Per cent of shares held by top holders
HolderShares% Held
Wynnefield Capital, Inc.as of 02 Jul 20244.41m14.28%
Legion Partners Asset Management LLCas of 08 Jul 20242.94m9.52%
Greenhaven Road Investment Management LPas of 30 Jun 20242.22m7.17%
22NW LPas of 30 Jun 20241.76m5.68%
325 Capital LLCas of 30 Jun 20241.34m4.34%
BlackRock Fund Advisorsas of 30 Jun 20241.33m4.31%
The Vanguard Group, Inc.as of 30 Jun 20241.27m4.11%
Morgan Stanley & Co. LLCas of 30 Jun 2024622.68k2.02%
Geode Capital Management LLCas of 30 Jun 2024541.98k1.75%
Visionary Wealth Advisors LLCas of 30 Jun 2024491.01k1.59%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.